Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Durable Improvement Shown in FVC and Across Multiple Measures
30 avr. 2023 14h10 HE
|
Pliant Therapeutics, Inc.
Bexotegrast was well tolerated up to 40 weeks of treatment with no drug-related serious adverse events Combination of bexotegrast with standard of care reduced FVC decline by 80% relative to standard...
Pliant Therapeutics to Participate in the 22nd Annual Needham Healthcare Conference
12 avr. 2023 08h01 HE
|
Pliant Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., April 12, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel...
Pliant Therapeutics Announces Poster Presentations at the 2023 American Thoracic Society International Conference
27 mars 2023 08h01 HE
|
Pliant Therapeutics, Inc.
Posters include data across biomarker, translation and clinical studies supportingdevelopment of bexotegrast (PLN-74809), a dual-selective inhibitor of αvβ6/αvβ1 integrins, in IPF Two posters...
Pliant Therapeutics Announces Positive DSMB Safety Review and Initiation of Enrollment of Phase 2a Trial of Bexotegrast (PLN-74809) at 320 mg Dose in Primary Sclerosing Cholangitis
13 mars 2023 08h01 HE
|
Pliant Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., March 13, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2022 Financial Results
09 mars 2023 16h05 HE
|
Pliant Therapeutics, Inc.
- Positive data from bexotegrast INTEGRIS-IPF 320 mg dose group demonstrated a continued favorable safety profile and statistically significant increases in FVC - INTEGRIS-IPF 320 mg dose 24-week...
Pliant Therapeutics Announces Appointments of Darren Cline and Thomas McCourt to Board of Directors
08 mars 2023 16h01 HE
|
Pliant Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., March 08, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel...
Pliant Therapeutics to Participate in Upcoming Investor Events
01 mars 2023 08h01 HE
|
Pliant Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel...
Pliant Therapeutics to Participate in Upcoming Investor Events
07 févr. 2023 08h01 HE
|
Pliant Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel...
Pliant Therapeutics Announces FDA Clearance of Investigational New Drug Application for PLN-101095, A Novel Integrin Inhibitor for the Treatment of Solid Tumors
02 févr. 2023 08h02 HE
|
Pliant Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel...
Pliant Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
27 janv. 2023 16h03 HE
|
Pliant Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 27, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel...